Dr. Saxena on the Importance of Initial Treatment Selection in ALK+ NSCLC

Video

Ashish Saxena, MD, PhD, discusses the importance of initial therapy selection in ALK-positive non–small cell lung cancer.

Ashish Saxena, MD, PhD, assistant attending physician, NewYork-Presbyterian Hospital, assistant professor of medicine, Weill Cornell Medical College, discusses the importance of initial therapy selection in ALK-positive non­—small cell lung cancer (NSCLC).

Patients will eventually develop resistance to ALK inhibitors, says Saxena. Secondary mutations may develop as a result of insufficient suppression of ALK or bypass pathways.

Specific secondary mutations that may arise following treatment with crizotinib (Xalkori) or alectinib (Alecensa) are sensitive to next-generation agents such as brigatinib (Alunbrig) and lorlatinib (Lorbrena).

As such, optimizing first-line treatment selection is necessary as it may influence which agents are available to the patient upon disease progression, concludes Saxena.

Recent Videos
Peter Cook, PhD, a senior research scientist at Seattle Children’s Research Institute
Nicholas Giovannone, PhD, a senior principal scientist at Regeneron
Brian Kim, MBA, the chief executive officer of Mission Bio
Kiran Musunuru, MD, PhD, a physician-scientist and Barry J. Gertz Professor for translational research in the Perelman School of Medicine at the University of Pennsylvania and CHOP and Rebecca Ahrens-Nicklas, MD, PhD, a physician-scientist and director of the Gene Therapy for Inherited Metabolic Disorders Frontier Program at CHOP
Ben Samelson-Jones, MD, PhD, an assistant professor of pediatric hematology at Perelman School of Medicine, University of Pennsylvania, and the associate director of clinical in vivo gene therapy at Children’s Hospital of Philadelphia
Kiran Musunuru, MD, PhD, a physician-scientist and Barry J. Gertz Professor for translational research in the Perelman School of Medicine at the University of Pennsylvania and CHOP and Rebecca Ahrens-Nicklas, MD, PhD, a physician-scientist and director of the Gene Therapy for Inherited Metabolic Disorders Frontier Program at CHOP
Roger Hajjar, MD, the director of the GCTI
Kiran Musunuru, MD, PhD, a physician-scientist and Barry J. Gertz Professor for translational research in the Perelman School of Medicine at the University of Pennsylvania and CHOP and Rebecca Ahrens-Nicklas, MD, PhD, a physician-scientist and director of the Gene Therapy for Inherited Metabolic Disorders Frontier Program at CHOP
Nicholas Giovannone, PhD, a senior principal scientist at Regeneron
Nathan Yozwiak, PhD, on Collaboration for Cell and Gene Therapy Development
Related Content
Atul Malhotra, MD, PhD, the head of the early neurodevelopment clinic at Monash Children's Hospital

Evaluating Autologous Cord Blood Derived Cells for the Treatment of Preterm Infants

Noah Stansfield
April 8th 2024
Article

Atul Malhotra, MD, PhD, the head of the early neurodevelopment clinic at Monash Children's Hospital, discussed his lab’s research in the field of neonatal cell therapy.

ImmunoLogic

ImmunoLogic, Episode 3: "Breaking the Brain’s Barrier: CAR T-Cells Take on Glioblastoma" With Marcela Maus, MD, PhD

Joseph A. Fraietta, PhD;Janna Minehart, MD;Marcela V. Maus, MD, PhD;Noah Stansfield;Matt Hoffman
April 8th 2025
Podcast

In Episode 3 of ImmunoLogic, Marcela Maus, MD, PhD, discussed her research on CAR-T for treating glioblastoma.

David Taylor, PhD

New Findings May Help Bolster CRISPR/Cas9 Accuracy

Victoria Johnson
March 4th 2022
Article

David Taylor, PhD, an assistant professor in the department of molecular biosciences at UT Austin, discussed the Cas9 research conducted between 2 labs at UT Austin.

ImmunoLogic

ImmunoLogic, Episode 2: "Charting New Frontiers in CAR T-Cell Safety" With Bruce Levine, PhD

Joseph A. Fraietta, PhD;Janna Minehart, MD;Noah Stansfield;Matt Hoffman
March 11th 2025
Podcast

In Episode 2 of ImmunoLogic, Bruce Levine, PhD, discussed the current the risk-benefit-ratio for CAR-T therapy.

Mariana Nacht, PhD

Gene Editing Trial Underway in Pediatric Methylmalonic Acidemia

Victoria Johnson
June 9th 2021
Article

The therapy utilizes LogicBio’s GeneRide technology to insert a corrective copy of the target gene via synthetic AAV vectors.

© 2025 MJH Life Sciences

All rights reserved.